Medicine price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.Ask about Poherdy

Is Poherdy available in Bahrain? Status, route and cost

A plain answer for families in Bahrain, checked against FDA, regulator and manufacturer sources on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Is Poherdy available in Bahrain?

Poherdy is not on NHRA's registered medicine list or its temporary importation list (checked 17 October 2026), but Perjeta, the medicine it copies, is registered in Bahrain. Poherdy is a biosimilar to Perjeta for HER2-positive breast cancer, given by infusion. If your oncologist needs Poherdy itself, the hospital asks NHRA for import permission.

Registration: Not on NHRA's registered list (7 September 2026) or temporary importation list (19 January 2025); Perjeta and Phesgo are registered.
Access route: First ask whether registered Perjeta or Phesgo meets the need; otherwise a hospital import request to NHRA.
Who acts: a government or private hospital in Bahrain, on the written request of your treating specialist.
Timeline: We give you a written timeline estimate for your case before you commit.
Price: Medicine price: quote on request. You get a written quote for your case before you commit.

Status in Bahrain, with dates

Not on NHRA's Registered Medicine Price List, version dated 7 September 2026 (5,560 entries), checked 17 October 2026. (source)
Not on NHRA's Temporary Importation Medicines List dated 19 January 2025, checked 17 October 2026. (source)
Perjeta 420 mg (pertuzumab, Roche) is registered as DRN-08305/13, and Phesgo (pertuzumab with trastuzumab, injected under the skin) as DRN-10386/23 and DRN-10387/23, on the same registered list. (source)
The FDA announced Poherdy's approval on 13 November 2025. (source)

What Poherdy is

Poherdy (pertuzumab-dpzb) is a biosimilar to Perjeta (pertuzumab). It is made by Shanghai Henlius Biotech and distributed in the US by Organon. The FDA announced its approval on 13 November 2025 as the first biosimilar to Perjeta, and also as interchangeable with Perjeta. In the US, interchangeable means a pharmacy may substitute it for Perjeta without contacting the prescriber, where state pharmacy law allows. Other countries set their own rules.

It is used together with trastuzumab and chemotherapy in adults with HER2-positive breast cancer: for metastatic breast cancer, with trastuzumab and docetaxel, when no anti-HER2 therapy or chemotherapy has been given for metastatic disease; before surgery (neoadjuvant) for locally advanced, inflammatory or early-stage breast cancer that is larger than 2 cm or has spread to lymph nodes; and after surgery (adjuvant) for early breast cancer at high risk of coming back.

How it is given and safety

It is given by intravenous infusion: a first dose of 840 mg over 60 minutes, then 420 mg every 3 weeks over 30 to 60 minutes. It comes as a 420 mg/14 mL single-dose vial that must be kept in a refrigerator at 2°C to 8°C, protected from light, and not frozen or shaken. Any shipment therefore needs a cold chain.

The US label has a boxed warning. Pertuzumab products can weaken the heart's pumping (a fall in LVEF, or heart failure), so heart function is checked before and during treatment. Exposure during pregnancy can cause the loss of the baby or birth defects. Other serious risks are infusion reactions and allergic reactions. Common side effects include diarrhea, hair loss, low white blood cell counts, nausea and tiredness.

How access works in Bahrain

Because Perjeta and Phesgo are registered in Bahrain, the first question for your oncologist is whether one of them meets the need. They contain the same active substance, pertuzumab.

NHRA's circular expects an unregistered medicine to have no registered alternative in Bahrain. A request for Poherdy itself therefore needs a clear clinical or supply reason, and NHRA decides. If Poherdy is still needed, this is how a hospital import request works:

Under NHRA Circular No. (41) of 2020, government and private hospitals must get NHRA's permission before they issue a purchase order for a medicine that is not registered in Bahrain.

The circular asks that the medicine is important and has no registered alternative in Bahrain, is registered with the Gulf Health Council or in a GCC country, is registered with a reference authority such as the US FDA, and is marketed in its country of origin.

Some medicines for rare diseases, emergencies and tumors with no registered alternative can be excused from the registration and marketing conditions, through NHRA's list of emergency medicines or with Board approval.

The request goes to NHRA by email with the application form, a Certificate of Pharmaceutical Product (CPP) or registration certificate from a reference authority, and a Good Manufacturing Practice (GMP) certificate. NHRA's 2022 application form is signed by the importing hospital, the agent or the marketing authorization holder, who takes full responsibility for the product's quality and safety.

NHRA updates its lists. Ask the hospital pharmacy to confirm the current status with NHRA's pharmaceutical products regulation section before anything is filed.

Who does what

Your treating specialist decides whether Poherdy is right for the patient and writes the clinical letter and prescription.
The hospital files the import request, receives the medicine and gives the infusion.
The National Health Regulatory Authority (NHRA) registers medicines and decides on any import request for a medicine that is not registered.
Henlius and Organon make Poherdy and decide where it is supplied.
Reserve Meds helps your family understand the steps, organizes records and communication, and, where an import is approved, arranges US supply through our licensed wholesale partner. We do not give medical advice.

Documents you will usually need

The pathology report confirming HER2-positive breast cancer, with the stage
A recent heart function result (LVEF), because the label requires a heart check before treatment
The oncologist's treatment plan, including the trastuzumab and chemotherapy that will be given with it
For an import request: the hospital's request form, its signed declaration of responsibility, written patient consent, and proof of the US FDA approval (we can supply the US prescribing information)

Steps

Doctor's letter. Your specialist writes the clinical letter and prescription.
Hospital request. The hospital pharmacy files the import request with NHRA.
Regulator decision. NHRA reviews the request and approves it or asks for more information.
US sourcing. Our US-licensed wholesale partner supplies the medicine, shipped refrigerated at 2°C to 8°C.
Hospital receipt. The hospital pharmacy receives the medicine and the infusion is given.

Timeline and cost

We give you a written timeline estimate for your case before you commit. The regulator, the hospital and the manufacturer set their own timelines.

Medicine price: quote on request. You get a written quote for your case before you commit. Your total cost depends on the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We coordinate access to FDA-approved medicines only. We help your family understand the route, organize records and communication with the doctor and hospital, and, where an import is approved, arrange US supply and refrigerated (2°C to 8°C) shipping through our licensed wholesale partner. Delivery follows the terms of the import approval and is confirmed in writing before you commit. We do not prescribe, and we do not decide what NHRA approves.

Ask about Poherdy in Bahrain

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is Poherdy registered in Bahrain?

Poherdy is not on NHRA's registered medicine list or its temporary importation list (checked 17 October 2026), but Perjeta, the medicine it copies, is registered in Bahrain. NHRA updates its lists. Ask the hospital pharmacy to confirm the current status with NHRA's pharmaceutical products regulation section before anything is filed.

How do patients in Bahrain get Poherdy?

Because Perjeta and Phesgo are registered in Bahrain, the first question for your oncologist is whether one of them meets the need. They contain the same active substance, pertuzumab. NHRA's circular expects an unregistered medicine to have no registered alternative in Bahrain. A request for Poherdy itself therefore needs a clear clinical or supply reason, and NHRA decides. Under NHRA Circular No. (41) of 2020, government and private hospitals must get NHRA's permission before they issue a purchase order for a medicine that is not registered in Bahrain.

How long does it take to get Poherdy in Bahrain?

We give you a written timeline estimate for your case before you commit. The regulator, the hospital and the manufacturer set their own timelines, and we tell you honestly what depends on them.

How much does Poherdy cost?

Medicine price: quote on request. You get a written quote for your case before you commit. Your total cost, including shipping, import steps and coordination, is quoted in writing before you commit. No hidden charges.

Is Poherdy the same as Perjeta?

Poherdy is a biosimilar to Perjeta, approved by the FDA as interchangeable with it in the US. Both contain pertuzumab and have the same uses on the US label. Whether one can replace the other in your country is decided by the local regulator and your oncologist.

Sources

Checked on 17 October 2026. Regulator rules and lists change. Your doctor, hospital pharmacy or the regulator confirms the current position before anything is filed.